The chronic co-administration of BERODUAL with other anticholinergic drugs has not been studied. Therefore, the chronic co-administration of BERODUAL with other anticholinergic drugs is not recommended.
Other beta-adrenergics, anticholinergics and xanthine derivatives (such as theophylline) may enhance the bronchodilatatory effect. The concurrent administration of other beta-mimetics, systemically available anticholinergics and xanthine derivatives (e.g. theophylline) may increase the adverse reactions.
A potentially serious reduction in bronchodilatation may occur during concurrent administration of beta-blockers.
Hypokalaemia induced by beta2-agonists may be increased by concomitant treatment with xanthine derivatives, corticosteroids, and diuretics. This should be taken into account particularly in patients with severe airway obstruction.
Hypokalaemia may result in an increased susceptibility to arrhythmias in patients receiving digoxin. Additionally, hypoxia may aggravate the effects of hypokalaemia on cardiac rhythm. It is recommended that serum potassium levels are monitored in such situations.
Beta2-agonist containing medicinal products should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta-adrenergic agonists may be enhanced.
Inhalation of halogenated hydrocarbon anaesthetics such as halothane, trichloroethylene and enflurane may increase the susceptibility on the cardiovascular effects of beta-agonists.